Successful Stem Cell Mobilization and CD34+ Cell Collection in a Poor Mobilizer: A Case Report Utilizing a Combination of Recombinant Growth Colony Stimulating Factor, Recombinant Human Growth Factor, and Plerixafor.

IF 0.7 Q4 PHARMACOLOGY & PHARMACY Journal of Research in Pharmacy Practice Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI:10.4103/jrpp.jrpp_46_23
Maliheh Kazemi Najafabadi, Azadeh Moghaddas, Mozhgan Karimifar, Ali Darakhshandeh
{"title":"Successful Stem Cell Mobilization and CD34+ Cell Collection in a Poor Mobilizer: A Case Report Utilizing a Combination of Recombinant Growth Colony Stimulating Factor, Recombinant Human Growth Factor, and Plerixafor.","authors":"Maliheh Kazemi Najafabadi, Azadeh Moghaddas, Mozhgan Karimifar, Ali Darakhshandeh","doi":"10.4103/jrpp.jrpp_46_23","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma is the most prevalent form of non-Hodgkin's lymphoma that is usually treated with chemoimmunotherapy. If the disease proves refractory or recurrent, the primary treatment approach involves high-dose chemotherapy with bone marrow transplantation. The collection of peripheral blood stem cells before transplantation plays a vital role in the treatment process, necessitating the mobilization of blood stem cells from the bone marrow to the peripheral blood. Despite using standard methods such as granulocyte colony-stimulating factor (G-CSF), chemotherapy, and plerixafor, some patients cannot collect an optimal count of CD34+ cells for transplantation. Managing these patients with poor mobilization poses significant challenges. In this article, we present a case of a poor mobilizer patient who achieved prosperous mobilization by using recombinant human G-CSF, recombinant human growth hormone, and plerixafor.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"12 3","pages":"110-113"},"PeriodicalIF":0.7000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071060/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_46_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Diffuse large B-cell lymphoma is the most prevalent form of non-Hodgkin's lymphoma that is usually treated with chemoimmunotherapy. If the disease proves refractory or recurrent, the primary treatment approach involves high-dose chemotherapy with bone marrow transplantation. The collection of peripheral blood stem cells before transplantation plays a vital role in the treatment process, necessitating the mobilization of blood stem cells from the bone marrow to the peripheral blood. Despite using standard methods such as granulocyte colony-stimulating factor (G-CSF), chemotherapy, and plerixafor, some patients cannot collect an optimal count of CD34+ cells for transplantation. Managing these patients with poor mobilization poses significant challenges. In this article, we present a case of a poor mobilizer patient who achieved prosperous mobilization by using recombinant human G-CSF, recombinant human growth hormone, and plerixafor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干细胞动员能力差者成功动员并采集 CD34+ 细胞:联合使用重组生长集落刺激因子、重组人生长因子和普乐沙福的病例报告。
弥漫大B细胞淋巴瘤是非霍奇金淋巴瘤中最常见的一种,通常采用化学免疫疗法进行治疗。如果病情难治或复发,主要治疗方法包括大剂量化疗和骨髓移植。移植前的外周血干细胞采集在治疗过程中起着至关重要的作用,必须将骨髓中的造血干细胞动员到外周血中。尽管使用了粒细胞集落刺激因子(G-CSF)、化疗和普利沙佛等标准方法,一些患者仍无法为移植收集到最佳数量的CD34+细胞。如何管理这些动员能力差的患者是一项重大挑战。在本文中,我们介绍了一例动员能力差的患者,该患者通过使用重组人G-CSF、重组人生长激素和普乐沙福实现了良好的动员。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Research in Pharmacy Practice
Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
8
审稿时长
21 weeks
期刊介绍: The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.
期刊最新文献
A Systematic Review of the Efficacy and Safety of Sirolimus (Rapamycin) in the Management of Infantile Hemangioma. Community Pharmacy Dispensing Errors: A Comprehensive Systematic Review on Trends and Solutions. Evaluating the Role of Machine Learning and Artificial Intelligence in Oncology Drug Repurposing Efforts. Evaluation of Synergistic Effect of Colistin with Levofloxacin and Meropenem against Multidrug-resistant Acinetobacter baumannii. Associations between Patients' Demographics and Chronic Medication Utilization in Internal Medicine: Cross-sectional Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1